You are currently browsing the archives for 17 June 2017.
Displaying 1 entry.

Cancer biomarker exams undervalued by patients and doctors.

Hayes led a blue-ribbon panel of professionals from universities, corporations, today in Science Translational Medicine insurance and advocacy companies to outline the problems in a commentary published. Tumor biomarker tests consider the genetic or molecular make-up of a tumor to determine whether the cancer will probably progress, and if so, if it is likely to react to treatment. If the check is good, it can benefit doctors decide when a patient can properly skip further therapy, or it can be used to direct which medication could be most likely to greatly help. The effect: ‘personalized medicine,’ this means patients get treatments that benefit them particularly and they avoid remedies – including their costs and side effects – that are not likely to change lives for them.